BNP Paribas Financial Markets Buys Shares of 249,128 Castle Biosciences, Inc. (NASDAQ:CSTL)

BNP Paribas Financial Markets purchased a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 249,128 shares of the company's stock, valued at approximately $6,639,000. BNP Paribas Financial Markets owned 0.89% of Castle Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Algert Global LLC increased its holdings in shares of Castle Biosciences by 11.3% in the fourth quarter. Algert Global LLC now owns 149,491 shares of the company's stock worth $3,984,000 after purchasing an additional 15,170 shares during the period. Northern Trust Corp increased its holdings in shares of Castle Biosciences by 8.7% in the fourth quarter. Northern Trust Corp now owns 284,587 shares of the company's stock worth $7,584,000 after purchasing an additional 22,657 shares during the period. Tudor Investment Corp ET AL increased its holdings in shares of Castle Biosciences by 41.6% in the fourth quarter. Tudor Investment Corp ET AL now owns 70,076 shares of the company's stock worth $1,868,000 after purchasing an additional 20,586 shares during the period. Aquatic Capital Management LLC bought a new position in shares of Castle Biosciences in the fourth quarter worth $539,000. Finally, Birchview Capital LP increased its holdings in shares of Castle Biosciences by 34.5% in the fourth quarter. Birchview Capital LP now owns 78,000 shares of the company's stock worth $2,079,000 after purchasing an additional 20,000 shares during the period. Institutional investors own 92.60% of the company's stock.

Insider Buying and Selling at Castle Biosciences

In other news, insider Derek J. Maetzold sold 2,130 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $19.52, for a total transaction of $41,577.60. Following the completion of the sale, the insider now directly owns 78,335 shares in the company, valued at approximately $1,529,099.20. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 27,454 shares of company stock worth $553,030 over the last three months. Company insiders own 7.20% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CSTL shares. Robert W. Baird upped their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Canaccord Genuity Group decreased their price target on shares of Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the stock a "buy" rating in a report on Friday, March 28th. Finally, Lake Street Capital reduced their target price on Castle Biosciences from $40.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences presently has an average rating of "Buy" and a consensus target price of $37.50.

Castle Biosciences Price Performance

CSTL traded up $0.27 during trading on Friday, reaching $16.75. The stock had a trading volume of 393,888 shares, compared to its average volume of 406,053. The stock has a market cap of $483.61 million, a PE ratio of 83.75 and a beta of 1.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. Castle Biosciences, Inc. has a one year low of $15.70 and a one year high of $35.84. The business has a 50-day moving average of $19.49 and a 200-day moving average of $24.99.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.12). Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The firm had revenue of $87.99 million during the quarter, compared to the consensus estimate of $80.40 million. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.